Combination of preoperative fibrinogen and D-dimer as a prognostic indicator in pancreatic ductal adenocarcinoma patients undergoing R0 resection

Table 6 Correlation between preoperative combined groups and clinicopathological characteristics in pancreatic ductal adenocarcinoma patients undergoing radical R0 resection, n (%)

Characteristics	Preoperative combined groups		P value
	Any-high group (n = 191)	Low-low group (n = 91)
Age (yr)			0.590
> 60	101 (35.8)	45 (16.0)
≤ 60	90 (31.9)	46 (16.3)
Sex			0.562
Male	100 (35.5)	51 (18.1)
Female	91 (32.3)	40 (14.2)
Blood type			0.480
A	54 (19.1)	33 (11.7)
B	65 (23.0)	28 (9.9)
AB	14 (5.0)	8 (2.8)
O	58 (20.6)	22 (7.8)
Diabetes			0.969
Absent	136 (48.2)	65 (23.0)
Present	55 (19.5)	26 (9.2)
Smoking status			0.433
Absent	143 (50.7)	72 (25.5)
Present	48 (17.0)	19 (6.7)
Alcohol consumption			0.531
Absent	161 (57.1)	74 (26.2)
Present	30 (10.6)	17 (6.0)
Family history of cancer			0.767
Absent	184 (65.2)	87 (30.9)
Present	7 (2.5)	4 (1.4)
Clinical symptoms			0.002
Absent	29 (10.3)	28 (9.9)
Present	162 (57.4)	63 (22.3)
Open surgery approach			0.128
Pancreaticoduodenectomy	94 (33.3)	36 (12.8)
Distal pancreatectomy with splenectomy	97 (34.4)	55 (19.5)
Tumor location			0.128
Head and neck	94 (33.3)	36 (12.8)
Body and tail	97 (34.4)	55 (19.5)
Degree of differentiation			0.392
Well	25 (8.9)	9 (3.2)
Moderately	148 (52.5)	69 (24.5)
Poorly	18 (6.4)	13 (4.6)
Lymphovascular invasion			0.322
Absent	134 (47.5)	69 (24.5)
Present	57 (20.2)	22 (7.8)
Perineural invasion			0.290
Absent	51 (18.1)	19 (6.7)
Present	140 (49.6)	72 (25.5)
Capsular invasion			0.159
Absent	29 (10.3)	20 (7.1)
Present	162 (57.4)	71 (25.2)
Maximal tumor diameter (cm)			0.021
> 4	68 (24.1)	20 (7.1)
≤ 4	123 (43.6)	71 (25.2)
T stage			0.048
T1	23 (8.2)	11 (3.9)
T2	99 (35.1)	60 (21.3)
T3	69 (24.5)	20 (7.1)
Lymph node metastasis			0.615
Absent	111 (39.4)	50 (17.7)
Present	80 (28.4)	41 (14.5)
N stage			0.026
N0	111 (39.4)	50 (17.7)
N1	55 (19.5)	37 (13.1)
N2	25 (8.9)	4 (1.4)
TNM stage			0.002
IA	13 (4.6)	7 (2.5)
IB	56 (19.9)	36 (12.8)
IIA	42 (14.9)	7 (2.5)
IIB	55 (19.5)	37 (13.1)
III	25 (8.9)	4 (1.4)
Preoperative CA19-9 level (U/mL)			0.095
> 336.4	58 (20.6)	19 (6.7)
≤ 336.4	133 (47.2)	72 (25.5)
Adjuvant therapy			0.198
Absent	89 (31.6)	35 (12.4)
Present	102 (36.2)	56 (19.9)

The any-high group for preoperative fibrinogen concentration > 3.31 g/L and/or preoperative D-dimer concentration > 0.53 mg/L group; the low-low group for preoperative fibrinogen concentration ≤ 3.31 g/L and preoperative D-dimer concentration ≤ 0.53 mg/L group. TNM: Tumor, node and metastasis.